{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:58:23Z","timestamp":1772135903997,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bevacizumab (bvz) is a first choice anti-angiogenic drug in oncology and is primarily administered in combination with chemotherapy. It has been hypothesized that anti-angiogenic drugs enhance efficacy of cytotoxic drugs by \u201cnormalizing\u201d abnormal tumor vessels and improving drug penetration. Nevertheless, the clinical relevance of this phenomenon is still unclear with several studies over recent years suggesting an opposing relationship. Herein, we sought to develop a new computational tool to interrogate anti-angiogenic drug scheduling with particular application in the setting of colorectal cancer (CRC). Specifically, we have employed a mathematical model of vascular tumour growth which interrogates the impact of anti-angiogenic treatment and chemotherapeutic treatment on tumour volume. Model predictions were validated using CRC xenografts which underwent treatment with a clinically relevant combinatorial anti-angiogenic regimen. Bayesian model selection revealed the most appropriate term for capturing the effect of treatments on the tumour size, and provided insights into a switch-like dependence of FOLFOX delivery on the tumour vasculature. Our experimental data and mathematical model suggest that delivering chemotherapy prior to bvz may be optimal in the colorectal cancer setting.<\/jats:p>","DOI":"10.1038\/s41598-018-29318-5","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T05:06:47Z","timestamp":1531976807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-angiogenic drug scheduling optimisation with application to colorectal cancer"],"prefix":"10.1038","volume":"8","author":[{"given":"M.","family":"Sturrock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6345","authenticated-orcid":false,"given":"I. S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Hannis Arba\u2019ie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6732-2966","authenticated-orcid":false,"given":"A. C.","family":"O\u2019Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Barat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Marston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. L.","family":"Coletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. T.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"Prehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,25]]},"reference":[{"key":"29318_CR1","first-page":"106","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman, J. Tumor angiogenesis in women with node-positive breast cancer. Cancer J Sci Am 1, 106\u2013108 (1995).","journal-title":"Cancer J Sci Am"},{"key":"29318_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249\u2013257 (2000).","journal-title":"Nature"},{"key":"29318_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N., Hillan, K. J., Gerber, H.-P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug discovery 3, 391\u2013400 (2004).","journal-title":"Nature reviews Drug discovery"},{"key":"29318_CR4","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335\u20132342 (2004).","journal-title":"N Engl J Med"},{"key":"29318_CR5","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine 357, 2666\u20132676 (2007).","journal-title":"New England Journal of Medicine"},{"key":"29318_CR6","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler, A. et al. Paclitaxel\u2013carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer. New England Journal of Medicine 355, 2542\u20132550 (2006).","journal-title":"New England Journal of Medicine"},{"key":"29318_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7, 987\u2013989 (2001).","journal-title":"Nat Med"},{"key":"29318_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","volume":"17","author":"NS Vasudev","year":"2014","unstructured":"Vasudev, N. S. & Reynolds, A. R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17, 471\u2013494 (2014).","journal-title":"Angiogenesis"},{"key":"29318_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","volume":"21","author":"AA Van der Veldt","year":"2012","unstructured":"Van der Veldt, A. A. et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21, 82\u201391 (2012).","journal-title":"Cancer Cell"},{"key":"29318_CR10","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1158\/0008-5472.CAN-12-3518","volume":"73","author":"M Arjaans","year":"2013","unstructured":"Arjaans, M. et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 73, 3347\u20133355 (2013).","journal-title":"Cancer Res"},{"key":"29318_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ijc.28046","volume":"133","author":"S Heskamp","year":"2013","unstructured":"Heskamp, S. et al. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int J Cancer 133, 307\u2013314 (2013).","journal-title":"Int J Cancer"},{"key":"29318_CR12","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.1158\/0008-5472.CAN-13-1989","volume":"73","author":"Y Huang","year":"2013","unstructured":"Huang, Y., Stylianopoulos, T., Duda, D. G., Fukumura, D. & Jain, R. K. Benefits of vascular normalization are dose and time dependent\u2013letter. Cancer Res 73, 7144\u20137146 (2013).","journal-title":"Cancer Res"},{"key":"29318_CR13","doi-asserted-by":"publisher","first-page":"6943","DOI":"10.1158\/1078-0432.CCR-13-1637","volume":"19","author":"NR Smith","year":"2013","unstructured":"Smith, N. R. et al. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res 19, 6943\u20136956 (2013).","journal-title":"Clin Cancer Res"},{"key":"29318_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3934\/mbe.2009.6.521","volume":"6","author":"P Hinow","year":"2009","unstructured":"Hinow, P. et al. A spatial model of tumor-host interaction: application of chemotherapy. Mathematical biosciences and engineering: MBE 6, 521 (2009).","journal-title":"Mathematical biosciences and engineering: MBE"},{"key":"29318_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.mcm.2005.05.008","volume":"41","author":"A Stephanou","year":"2005","unstructured":"Stephanou, A., McDougall, S. R., Anderson, A. R. & Chaplain, M. A. Mathematical modelling of flow in 2D and 3D vascular networks: applications to anti-angiogenic and chemotherapeutic drug strategies. Mathematical and Computer Modelling 41, 1137\u20131156 (2005).","journal-title":"Mathematical and Computer Modelling"},{"key":"29318_CR16","doi-asserted-by":"publisher","first-page":"e1003120","DOI":"10.1371\/journal.pcbi.1003120","volume":"9","author":"GG Powathil","year":"2013","unstructured":"Powathil, G. G., Adamson, D. J. & Chaplain, M. A. Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: clinical insights from a computational model. PLoS computational biology 9, e1003120 (2013).","journal-title":"PLoS computational biology"},{"key":"29318_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtbi.2012.05.015","volume":"308","author":"GG Powathil","year":"2012","unstructured":"Powathil, G. G., Gordon, K. E., Hill, L. A. & Chaplain, M. A. Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: biological insights from a hybrid multiscale cellular automaton model. Journal of theoretical biology 308, 1\u201319 (2012).","journal-title":"Journal of theoretical biology"},{"key":"29318_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-016-0114-9","volume":"11","author":"KD Argyri","year":"2016","unstructured":"Argyri, K. D., Dionysiou, D. D., Misichroni, F. D. & Stamatakos, G. S. Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data. Biol Direct 11, 12 (2016).","journal-title":"Biol Direct"},{"key":"29318_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3934\/mbe.2011.8.591","volume":"8","author":"J Poleszczuk","year":"2011","unstructured":"Poleszczuk, J., Bodnar, M. & Fory\u015b, U. New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model. Mathematical biosciences and engineering: MBE 8, 591\u2013603 (2011).","journal-title":"Mathematical biosciences and engineering: MBE"},{"key":"29318_CR20","first-page":"4770","volume":"59","author":"P Hahnfeldt","year":"1999","unstructured":"Hahnfeldt, P., Panigrahy, D., Folkman, J. & Hlatky, L. Tumor development under angiogenic signaling. Cancer research 59, 4770\u20134775 (1999).","journal-title":"Cancer research"},{"key":"29318_CR21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1039\/c0mb00107d","volume":"7","author":"K Erguler","year":"2011","unstructured":"Erguler, K. & Stumpf, M. P. Practical limits for reverse engineering of dynamical systems: a statistical analysis of sensitivity and parameter inferability in systems biology models. Mol Biosyst 7, 1593\u20131602 (2011).","journal-title":"Mol Biosyst"},{"key":"29318_CR22","doi-asserted-by":"publisher","first-page":"23087","DOI":"10.18632\/oncotarget.15484","volume":"8","author":"S Mollard","year":"2017","unstructured":"Mollard, S. et al. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis. Oncotarget 8, 23087 (2017).","journal-title":"Oncotarget"},{"key":"29318_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.future.2016.03.026","volume":"67","author":"G Kang","year":"2017","unstructured":"Kang, G. et al. Colorectal tumour simulation using agent based modelling and high performance computing. Future Generation Computer Systems 67, 397\u2013408 (2017).","journal-title":"Future Generation Computer Systems"},{"key":"29318_CR24","doi-asserted-by":"publisher","first-page":"e19989","DOI":"10.1371\/journal.pone.0019989","volume":"6","author":"RD Travasso","year":"2011","unstructured":"Travasso, R. D., Corvera Poire, E., Castro, M., Rodriguez-Manzaneque, J. C. & Hernandez-Machado, A. Tumor angiogenesis and vascular patterning: a mathematical model. PLoS One 6, e19989 (2011).","journal-title":"PLoS One"},{"key":"29318_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145\u2013147 (2004).","journal-title":"Nat Med"},{"key":"29318_CR26","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1158\/0008-5472.CAN-13-2986","volume":"74","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee, S. et al. Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. Cancer Res 74, 2816\u20132824 (2014).","journal-title":"Cancer Res"},{"key":"29318_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10479-011-0869-4","volume":"221","author":"J Shi","year":"2014","unstructured":"Shi, J., Alagoz, O., Erenay, F. S. & Su, Q. A survey of optimization models on cancer chemotherapy treatment planning. Annals of Operations Research 221, 331\u2013356 (2014).","journal-title":"Annals of Operations Research"},{"key":"29318_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/830515","volume":"2011","author":"Jana L. Gevertz","year":"2011","unstructured":"Gevertz, J. L. Computational modeling of tumor response to vascular-targeting therapies\u2014part I: validation. Computational and mathematical methods in medicine 2011, (2011).","journal-title":"Computational and Mathematical Methods in Medicine"},{"key":"29318_CR29","doi-asserted-by":"publisher","first-page":"18632","DOI":"10.1073\/pnas.1318415110","volume":"110","author":"T Stylianopoulos","year":"2013","unstructured":"Stylianopoulos, T. & Jain, R. K. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci USA 110, 18632\u201318637 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"29318_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","volume":"14","author":"Y Shaked","year":"2008","unstructured":"Shaked, Y. et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14, 263\u2013273 (2008).","journal-title":"Cancer Cell"},{"key":"29318_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1091-6","volume":"15","author":"AS Fung","year":"2015","unstructured":"Fung, A. S., Lee, C., Yu, M. & Tannock, I. F. The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts. BMC Cancer 15, 112 (2015).","journal-title":"BMC Cancer"},{"key":"29318_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nrc.2017.85","volume":"17","author":"AT Byrne","year":"2017","unstructured":"Byrne, A. T. et al. Interrogating open issues in cancer medicine with patient-derived xenografts. Nat Rev Cancer 17, 632 (2017).","journal-title":"Nat Rev Cancer"},{"key":"29318_CR33","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1158\/1078-0432.CCR-15-2879","volume":"22","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clin Cancer Res 22, 4057\u20134066 (2016).","journal-title":"Clin Cancer Res"},{"key":"29318_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2102-y","volume":"16","author":"A Avallone","year":"2016","unstructured":"Avallone, A. et al. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX\/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). BMC Cancer 16, 69 (2016).","journal-title":"BMC Cancer"},{"key":"29318_CR35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1208\/s12248-012-9342-9","volume":"14","author":"F Wu","year":"2012","unstructured":"Wu, F., Tamhane, M. & Morris, M. E. Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice. The AAPS journal 14, 252\u2013261 (2012).","journal-title":"The AAPS journal"},{"key":"29318_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3109\/00498254.2014.943335","volume":"45","author":"S Kobuchi","year":"2015","unstructured":"Kobuchi, S. et al. Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats. Xenobiotica 45, 19\u201328 (2015).","journal-title":"Xenobiotica"},{"key":"29318_CR37","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","volume":"62","author":"JF Lu","year":"2008","unstructured":"Lu, J. F. et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62, 779\u2013786 (2008).","journal-title":"Cancer Chemother Pharmacol"},{"key":"29318_CR38","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz, L. B. et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology 26, 2013\u20132019 (2008).","journal-title":"Journal of Clinical Oncology"},{"key":"29318_CR39","unstructured":"Hacker, M., Messer, W. S. & Bachmann, K. A. Pharmacology: Principles and Practice (Elsevier Science, 2009)."},{"key":"29318_CR40","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.2174\/1381612819666131125150434","volume":"20","author":"H Enderling","year":"2014","unstructured":"Enderling, H. & Chaplain, M. Mathematical modeling of tumor growth and treatment. Current pharmaceutical design 20, 4934\u20134940 (2014).","journal-title":"Current pharmaceutical design"},{"key":"29318_CR41","doi-asserted-by":"crossref","unstructured":"Rackauckas, C. & Nie, Q. Differential Equations. jl\u2013A Performant and Feature-Rich Ecosystem for Solving Differential Equations in Julia. Journal of Open Research Software 5, (2017).","DOI":"10.5334\/jors.151"},{"key":"29318_CR42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1145\/1089014.1089020","volume":"31","author":"AC Hindmarsh","year":"2005","unstructured":"Hindmarsh, A. C. et al. SUNDIALS: Suite of nonlinear and differential\/algebraic equation solvers. ACM Transactions on Mathematical Software (TOMS) 31, 363\u2013396 (2005).","journal-title":"ACM Transactions on Mathematical Software (TOMS)"},{"key":"29318_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1098\/rsif.2008.0172","volume":"6","author":"T Toni","year":"2009","unstructured":"Toni, T., Welch, D., Strelkowa, N., Ipsen, A. & Stumpf, M. P. Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systems. J R Soc Interface 6, 187\u2013202 (2009).","journal-title":"J R Soc Interface"},{"key":"29318_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jtbi.2016.04.028","volume":"402","author":"MO Besenhard","year":"2016","unstructured":"Besenhard, M. O. et al. Modelling tumour cell proliferation from vascular structure using tissue decomposition into avascular elements. J Theor Biol 402, 129\u2013143 (2016).","journal-title":"J Theor Biol"},{"key":"29318_CR45","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1745-7254.2005.00530.x","volume":"26","author":"Y Jin","year":"2005","unstructured":"Jin, Y. et al. Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice. Acta Pharmacol Sin 26, 250\u2013256 (2005).","journal-title":"Acta Pharmacol Sin"},{"key":"29318_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.clpt.2004.03.008","volume":"76","author":"SP Joel","year":"2004","unstructured":"Joel, S. P. et al. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. Clin Pharmacol Ther 76, 45\u201354 (2004).","journal-title":"Clin Pharmacol Ther"},{"key":"29318_CR47","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S0959-8049(99)00149-5","volume":"35","author":"F Maindrault-Goebel","year":"1999","unstructured":"Maindrault-Goebel, F. et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35, 1338\u20131342 (1999).","journal-title":"Eur J Cancer"}],"updated-by":[{"DOI":"10.1038\/s41598-018-31456-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29318-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29318-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29318-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:49:06Z","timestamp":1671590946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29318-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["29318"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-29318-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733699856.793549350","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,25]]},"assertion":[{"value":"2 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11182"}}